The DOI matches its Crossref record; 101 of the 103 references it cites were found in a registry or an index.
Role of medical therapy in the management of uterine adenomyosis
Open accessAbstract
Adenomyosis is a benign uterine condition affecting women at various ages with different symptoms. The management of these patients is still controversial. Few clinical studies focusing on medical or surgical treatment for adenomyosis have been performed. No drug is currently labelled for adenomyosis and there are no specific guidelines to follow for the best management. Anyhow, medical treatments are effective in improving symptoms (pain, abnormal uterine bleeding and infertility). The rationale for using medical treatment is based on the pathogenetic mechanisms of adenomyosis: sex steroid hormones aberrations, impaired apoptosis, and increased inflammation. Several nonhormonal (i.e., nonsteroidal anti-inflammatory drugs) and hormonal treatments (i.e., progestins, oral contraceptives, gonadotropin-releasing hormone analogues) are currently used off-label to control pain symptoms and abnormal uterine bleeding in adenomyosis. Gonadotropin-releasing hormone analogues are indicated before fertility treatments to improve the chances of pregnancy in infertile women with adenomyosis. An antiproliferative and anti-inflammatory effect of progestins, such as dienogest, danazol and norethindrone acetate, suggests their use in medical management of adenomyosis mainly to control pain symptoms. On the other hand, the intrauterine device releasing levonorgestrel resulted is extremely effective in resolving abnormal uterine bleeding and reducing uterine volume in a long-term management plan. Based on new findings on pathogenetic mechanisms, new drugs are under development for the treatment of adenomyosis, such as selective progesterone receptor modulators, aromatase inhibitors, valproic acid, and anti-platelets therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The clinical treatment strategy for the two diseases also seems to be similar, and the drugs to treat the two diseases can be used interchangeably [11].”
From The Pathogenesis of Adenomyosis vis-à-vis Endometriosis (2020) · cites this paper as [11]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
den Bosch, T. V., Dueholm, M., Leone, F. P., Valentin, L., Rasmussen, C. K., Votino, A., Schoubroeck, D. V., Landolfo, C., Installé, A., Guerriero, S., et al. (2015) · Ultrasound in Obstetrics and Gynecology · doi:10.1002/uog.14806 · Cited by 776
Nonsteroidal anti-inflammatory drugs for dysmenorrhoea
Marjoribanks, J., Ayeleke, R. O., Farquhar, C. M., & Proctor, M. L. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001751.pub3 · Cited by 573
Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist
Taylor, H. S., Giudice, L. C., Lessey, B. A., Abrao, M. S., Kotarski, J., Archer, D. F., Diamond, M. P., Surrey, E., Johnson, N. P., Watts, N. B., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1700089 · Cited by 511
Naftalin, J., Hoo, W., Pateman, K., Mavrelos, D., Holland, T., & Jurkovic, D. (2012) · Human Reproduction · doi:10.1093/humrep/des332 · Cited by 337
Pathogenesis of adenomyosis, an update on molecular mechanisms
Vannuccini, S., Tosti, C., Carmona, F., Huang, S. J., Chapron, C., Guo, S.-W., & Petraglia, F. (2017) · Reproductive BioMedicine Online · doi:10.1016/j.rbmo.2017.06.016 · Cited by 326
Self-citationChwalisz, K., Perez, M. C., DeManno, D., Winkel, C., Schubert, G., & Elger, W. (2005) · Endocrine Reviews · doi:10.1210/er.2005-0001 · Cited by 310
Kitawaki, J., Noguchi, T., Amatsu, T., Maeda, K., Tsukamoto, K., Yamamoto, T., Fushiki, S., Osawa, Y., & Honjo, H. (1997) · Biology of Reproduction · doi:10.1095/biolreprod57.3.514 · Cited by 305
Chapron, C., Tosti, C., Marcellin, L., Bourdon, M., Lafay-Pillet, M.-C., Millischer, A.-E., Streuli, I., Borghese, B., Petraglia, F., & Santulli, P. (2017) · Human Reproduction · doi:10.1093/humrep/dex088 · Cited by 294
Self-citationEffects of adenomyosis on in vitro fertilization treatment outcomes: a meta-analysis
Younes, G., & Tulandi, T. (2017) · Fertility and Sterility · doi:10.1016/j.fertnstert.2017.06.025 · Cited by 272
Khan, K. N., Kitajima, M., Hiraki, K., Fujishita, A., Sekine, I., Ishimaru, T., & Masuzaki, H. (2009) · Human Reproduction · doi:10.1093/humrep/dep437 · Cited by 269
Research works printed but not linked: 1
- Badawy, 2012, Aromatase inhibitors or gonadotropin-releasing hormone agonists for the management of uterine adenomyosis: A randomized controlled trial. Acta Obstet Gynecol, Scand, 91, 489
Cited by
Sorted by citations
Diagnosing adenomyosis: an integrated clinical and imaging approach
Chapron, C., Vannuccini, S., Santulli, P., Abrão, M. S., Carmona, F., Fraser, I. S., Gordts, S., Guo, S., Just, P., Noël, J., et al. (2020) · Human Reproduction Update · doi:10.1093/humupd/dmz049 · Cited by 439
Self-citationAdenomyosis: Mechanisms and Pathogenesis
Zhai, J., Vannuccini, S., Petraglia, F., & Giudice, L. C. (2020) · Seminars in Reproductive Medicine · doi:10.1055/s-0040-1716687 · Cited by 331
Self-citationRecent advances in understanding and managing adenomyosis
Vannuccini, S., & Petraglia, F. (2019) · F1000Research · doi:10.12688/f1000research.17242.1 · Cited by 298
Self-citationAdenomyosis incidence, prevalence and treatment: United States population-based study 2006–2015
Yu, O., Schulze-Rath, R., Grafton, J., Hansen, K., Scholes, D., & Reed, S. D. (2020) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2020.01.016 · Cited by 200
Progesterone Actions and Resistance in Gynecological Disorders
MacLean, J. A., & Hayashi, K. (2022) · Cells · doi:10.3390/cells11040647 · Cited by 199
Metadata
- Authors
- Vannuccini, S., Luisi, S., Tosti, C., Sorbi, F., & Petraglia, F.
- Affiliations
- Azienda Ospedaliero-Universitaria Careggi (IT)
- University of Siena (IT)
- Corresponding author
- Petraglia, Felice
- Venue
- Fertility and Sterility
- Publisher
- Elsevier BV
- Published
- 2018-03
- Volume
- 109
- Issue
- 3
- Pages
- 398-405
- ISSN
- 0015-0282 (ISSN-L)
- OpenAlex
- W2790094279
- Cited by
- 231
- References
- 103
- Citations by year
- 2026: 20 · 2025: 24 · 2024: 33 · 2023: 37 · 2022: 40 · 2021: 38 · 2020: 20 · 2019: 17 · 2018: 2
- FWCI
- 2.91
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Fertility and Sterility (publishedVersion)
- PubMed (publishedVersion)
- Florence Research (University of Florence) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
- Health Sciences › Medicine › Obstetrics and Gynecology › Uterine Myomas and Treatments
- Health Sciences › Medicine › Obstetrics and Gynecology › Gynecological conditions and treatments
- Keywords
- adenomyosis, medical therapy, hormone therapy, GnRH analogues, progestins, dienogest, danazol, norethindrone acetate, levonorgestrel intrauterine device, nonsteroidal anti-inflammatory drugs, abnormal uterine bleeding, dysmenorrhea, infertility, sex hormones, apoptosis, inflammation, selective progesterone receptor modulators, aromatase inhibitors, valproic acid, antiplatelet therapy
- MeSH terms
- Animals, Anti-Inflammatory Agents, Non-Steroidal, Female, Fertility Agents, Female, Humans, Intrauterine Devices, Medicated, Gonadotropin-Releasing Hormone, Progestins, Uterine Diseases, Drugs, Investigational, Treatment Outcome, Adenomyosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
